Cipla arm secures marketing rights for cancer drug in US

Cipla USA, Inc, a subsidiary of the company will be marketing the drug in strengths of 150 and 500 mg tablets.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news